Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Targeted therapy in lymphoma.

Johnston PB, Yuan R, Cavalli F, Witzig TE.

J Hematol Oncol. 2010 Nov 23;3:45. doi: 10.1186/1756-8722-3-45. Review.

2.

Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.

Wang M, Popplewell LL, Collins RH Jr, Winter JN, Goy A, Kaminski MS, Bartlett NL, Johnston PB, Lister J, Fanning SR, Tuscano JM, Beck JT, Kaya H, Robeva A, Fan J, Klimovsky J, Cheung W, Cherfi A, O'Connor OA.

Br J Haematol. 2014 May;165(4):510-8. doi: 10.1111/bjh.12780. Epub 2014 Mar 2.

3.

Proteasome inhibitors in mantle cell lymphoma.

Holkova B, Grant S.

Best Pract Res Clin Haematol. 2012 Jun;25(2):133-41. doi: 10.1016/j.beha.2012.04.007. Epub 2012 May 16. Review.

4.

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.

Ghobrial IM, Weller E, Vij R, Munshi NC, Banwait R, Bagshaw M, Schlossman R, Leduc R, Chuma S, Kunsman J, Laubach J, Jakubowiak AJ, Maiso P, Roccaro A, Armand P, Dollard A, Warren D, Harris B, Poon T, Sam A, Rodig S, Anderson KC, Richardson PG.

Lancet Oncol. 2011 Mar;12(3):263-72. doi: 10.1016/S1470-2045(11)70028-6. Epub 2011 Feb 21.

PMID:
21345726
5.

The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia.

Saunders P, Cisterne A, Weiss J, Bradstock KF, Bendall LJ.

Haematologica. 2011 Jan;96(1):69-77. doi: 10.3324/haematol.2010.026997. Epub 2010 Oct 15.

6.

[Current development of new drugs in malignant lymphoma].

Ogura M.

Nihon Rinsho. 2012 Apr;70 Suppl 2:715-30. Japanese. No abstract available.

PMID:
23134034
7.

Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.

Huang JJ, Li ZM, Huang Y, Huang Y, Tian Y, He XX, Xiao J, Lin TY.

Invest New Drugs. 2012 Feb;30(1):223-35. doi: 10.1007/s10637-010-9558-4. Epub 2010 Oct 20.

PMID:
20960030
8.

The role of bortezomib in the treatment of lymphoma.

Barr P, Fisher R, Friedberg J.

Cancer Invest. 2007 Dec;25(8):766-75. Review.

PMID:
18058474
9.

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.

Pal SK, Figlin RA.

Target Oncol. 2011 Mar;6(1):5-16. doi: 10.1007/s11523-011-0172-y. Epub 2011 Apr 12. Review.

10.

Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia.

Roccaro AM, Sacco A, Jia X, Banwait R, Maiso P, Azab F, Flores L, Manier S, Azab AK, Ghobrial IM.

Clin Cancer Res. 2012 Dec 15;18(24):6609-22. doi: 10.1158/1078-0432.CCR-12-1532. Epub 2012 Oct 9.

11.

Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.

Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-Mancini A, Ma E, Shi H, Comenzo RL.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):380-8. doi: 10.1016/j.clml.2014.03.005. Epub 2014 Jun 11.

PMID:
25023616
12.
13.
14.

Clinical development of mTOR inhibitors: a focus on lymphoma.

Smith SM.

Rev Recent Clin Trials. 2007 May;2(2):103-10. Review.

PMID:
18473994
15.

Proteasome inhibitor, bortezomib, for myeloma and lymphoma.

Tobinai K.

Int J Clin Oncol. 2007 Oct;12(5):318-26. Epub 2007 Oct 22. Review.

PMID:
17929113
16.

The future of small molecule inhibitors in lymphoma.

Gerecitano J.

Curr Oncol Rep. 2009 Sep;11(5):378-85. Review.

PMID:
19679013
17.

Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.

Zinzani PL, Pellegrini C, Merla E, Ballerini F, Fabbri A, Guarini A, Pavone V, Quintini G, Puccini B, Vigliotti ML, Stefoni V, Derenzini E, Broccoli A, Gandolfi L, Quirini F, Casadei B, Argnani L, Baccarani M.

Hematol Oncol. 2013 Dec;31(4):179-82. doi: 10.1002/hon.2036. Epub 2012 Oct 29.

PMID:
23108928
18.

Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.

Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP.

Curr Cancer Drug Targets. 2011 Mar;11(3):239-53. Review.

19.

Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.

Leonard JP, Furman RR, Coleman M.

Int J Cancer. 2006 Sep 1;119(5):971-9. Review.

20.

New therapeutic strategies for soft tissue sarcomas.

von Mehren M.

Curr Treat Options Oncol. 2003 Dec;4(6):441-51. Review.

PMID:
14585225

Supplemental Content

Support Center